Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Medical Care|August 23, 2007
Evaluating chronic disease for heterogeneous populations: the case of arthritisRobert L Scharff, Amber JessupApplied Health Economics and Health Policy|September 8, 2016
Promoting Antibacterial Drug Development: Select Policies and ChallengesAylin Sertkaya, Amber Jessup, Hui-Hsing WongJAMA Network Open|September 14, 2022
Estimated Cost of Developing a Therapeutic Complex Medical Device in the USAylin Sertkaya, Rebecca DeVries, Amber Jessup, et al.Clinical Trials (London, England)|February 25, 2016
Key cost drivers of pharmaceutical clinical trials in the United StatesAylin Sertkaya, Hui-Hsing Wong, Amber Jessup, et al.JAMA Network Open|June 28, 2024
Costs of Drug Development and Research and Development Intensity in the US, 2000-2018Aylin Sertkaya, Trinidad Beleche, Amber Jessup, et al.Health Economics|March 18, 2006
Valuing avoided morbidity using meta-regression analysis: what can health status measures and QALYs tell us about WTP?George Van Houtven, John Powers, Amber Jessup, et al.American Journal of Infection Control|December 24, 2018
Societal willingness to pay to avoid mortality and morbidity from Clostridioides difficile and carbapenem-resistant Enterobacteriaceae infections in the United StatesAylin Sertkaya, Hui-Hsing Wong, Daniel H Ertis, et al.Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 7, 2021
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National SurveyAllison R Kolbe, Aaron Kearsley, Lubna Merchant, et al.The American Journal of Managed Care|July 19, 2022
Projected US savings from biosimilars, 2021-2025Andrew Mulcahy, Christine Buttorff, Kenneth Finegold, et al.International Journal of Antimicrobial Agents|December 10, 2023
Assessing the state of antibacterial drug discovery through patent analysisAylin Sertkaya, J Daniel McGeeney, Casey Sullivan, et al.Pageof 2